Company news

Sinotherapeutics, Inc. Class A (SSE:688247) news

Sinotherapeutics, Inc. Class A news releases on 6ix. Latest, Sep 11, 2026: "SINOTHERAPEUTICS INC."Announcement on Change of Signing Certified Public Accountant

Sinotherapeutics, Inc. Class A (SSE:688247) news

Press releases & updates

"SINOTHERAPEUTICS INC."Announcement on Change of Signing Certified Public Accountant

"SINOTHERAPEUTICS INC."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026

"SINOTHERAPEUTICS INC."Announcement on Using Certain Idle Raised Funds for Cash Management

"SINOTHERAPEUTICS INC."Announcement on Voluntary Disclosure of Proposed Selection in the National Centralized Drug Procurement

"SINOTHERAPEUTICS INC."Announcement on Voluntary Disclosure of Approval of Posaconazole Enteric-coated Tablets via the EU Decentralised Procedure (DCP)

"SINOTHERAPEUTICS INC."Announcement on Voluntary Disclosure of Doxofylline Tablets Passing the Consistency Evaluation of Generic Drugs and the Addition of a New Specification

"SINOTHERAPEUTICS INC."Announcement on Abnormal Fluctuations in Stock Trading

Announcement on Implementation of Dividend Distribution for 2025

Announcement on the Expiry of Planned Time for Shareholders with Over 5% Shares to Reduce Shares and Results of Shareholding Reduction

Senior Management Member" -- Announcement on Completing Term Change and Election of the Board of Directors and Appointing Senior Management Members and Securities Affairs Representative, as well as Departure of Core Technical Personnel

Announcement on Voluntary Disclosure of Obtaining the Colombian INVIMA Approval for Bupropion Hydrochloride Extended-release Tablets

Notice on Convening the 2025 Annual General Meeting

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference

Indicative Announcement on Equity Change of Shareholder with Over 5% Shares Reaching an Integral Multiple of 1% and 5% Scale

Announcement on Resolutions of the 25th Meeting of the 2nd Board of Directors

Publicity Explanation and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2025 Restricted Stock Incentive Plan

Announcement on Voluntary Disclosure of Sinotherapeutics® Tomato Red Grape Seed Extract Tablets Obtaining the Domestic Health Food Registration Certificate

Notice on Convening the 1st Extraordinary General Meeting in 2026

Announcement on Voluntary Disclosure of Clinical Trial Applications for Collaborative Product Enzalutamide Tablets Approved by China NMPA

Announcement on Approval by Shanghai Municipal State-owned Assets Supervision and Administration Commission for Abstract of 2025 Restricted Stock Incentive Plan (Revised Draft)

Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Vitamin K1 Tablets

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Continuation Drug Procurement

Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares

Announcement on Provision for Asset Impairment for 2025

Summary Announcement on 2025 Restricted Stock Incentive Plan (Revised Draft)

Announcement on Voluntary Disclosure of Clinical Trial Applications for Eisaiconazole Sulfate for Injection Approved by China NMPA

Announcement on Appointment of Senior Management Members

Announcement on Postponement of Investment Projects Financed by Raised Funds

Announcement on Voluntary Disclosure of the Renewal and Inclusion of the Company’s Product in the National Medical Insurance Catalog

Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025

Report for Q3 2025

Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Centralized Drug Procurement

Indicative Announcement on Equity Change of Shareholding Reduction by Shareholder with Over 5% Shares to Less than 5%

Announcement on Changing Signatory Certified Public Accountant

Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Sitagliptin and Metformin Hydrochloride Sustained-release Tablets

Announcement on Release of Pledge of Partial Shares Held by Shareholders with Over 5% Shares

Announcement on Implementation of Semi-annual Dividend Distribution for 2025

Announcement on Pledge of Partial Shares by Shareholders with Over 5% of Shares

Announcement on Increasing Estimated Amount of Daily Related Party Transactions in 2025

Announcement on Voluntary Disclosure of Obtaining Marketing Approval by the National Medical Products Administration for the New Strength of Sitagliptin and Metformin Hydrochloride Sustained-release Tablets

Announcement on Cancellation of Some Accounts for Raised Funds

Announcement on Attending Semi-annual Collective Performance Briefing for Enterprises in Biological Products and CXO Industries on SSE STAR Market 2025

Special Report on Semi-annual Deposit and Use of Raised Funds in 2025

Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering

Announcement on Using Partial Idle Raised Funds for Cash Management

Announcement on Voluntary Disclosure of Obtaining EU GMP Certification by the Wholly-owned Subsidiary

Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Enzalutamide Tablets

Announcement on Implementation of Dividend Distribution for 2024

Announcement on Resolution of the 2024 Annual General Meeting